Baxalta (NYSE:BXLT) Receiving Somewhat Favorable News Coverage, Analysis Shows
Media coverage about Baxalta (NYSE:BXLT) has trended somewhat positive on Tuesday, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Baxalta earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.2375258536788 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Baxalta (BXLT) opened at $46.02 on Tuesday. Baxalta has a twelve month low of $29.83 and a twelve month high of $46.52.
ILLEGAL ACTIVITY WARNING: This story was first reported by Marea Informative and is the property of of Marea Informative. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.mareainformativa.com/2018/01/30/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-baxalta-bxlt-share-price-updated-updated-updated.html.
Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta’s categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR.
Receive News & Ratings for Baxalta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxalta and related companies with MarketBeat.com's FREE daily email newsletter.